中国新药杂志

利伐沙班致出血不良反应的国内外文献分析

PDF下载

孙雪 , 郭彩会 , 宋浩静 , 董占军

中国新药杂志 | 药物安全与合理应用 2021,30(21): 2003-2008

收起

中国新药杂志 |药物安全与合理应用 2021 , 30 (21) : 2003 -2008

利伐沙班致出血不良反应的国内外文献分析

全屏

[Author(id=1322906912941028012, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=804048521@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906913012331182, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906912941028012, language=EN, stringName=Xue SUN, firstName=Xue, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906913096217263, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906912941028012, language=CN, stringName=孙雪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省人民医院药学部，石家庄　050051, bio={"content":"

孙雪，女，主管药师，硕士，主要从事临床药理学工作。E-mail：804048521@qq.com。

"}, bioImg=null, bioContent=

孙雪，女，主管药师，硕士，主要从事临床药理学工作。E-mail：804048521@qq.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906911632405160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, xref=null, ext=[AuthorCompanyExt(id=1322906911670153897, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China), AuthorCompanyExt(id=1322906911691125418, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省人民医院药学部，石家庄　050051)])]), Author(id=1322906913293349553, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906913389818547, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913293349553, language=EN, stringName=Cai-hui GUO, firstName=Cai-hui, middleName=null, lastName=GUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906913465316020, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913293349553, language=CN, stringName=郭彩会, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省人民医院药学部，石家庄　050051, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906911632405160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, xref=null, ext=[AuthorCompanyExt(id=1322906911670153897, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China), AuthorCompanyExt(id=1322906911691125418, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省人民医院药学部，石家庄　050051)])]), Author(id=1322906913532424886, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906913607922360, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913532424886, language=EN, stringName=Hao-jing SONG, firstName=Hao-jing, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906913675031225, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913532424886, language=CN, stringName=宋浩静, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省人民医院药学部，石家庄　050051, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906911632405160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, xref=null, ext=[AuthorCompanyExt(id=1322906911670153897, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China), AuthorCompanyExt(id=1322906911691125418, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省人民医院药学部，石家庄　050051)])]), Author(id=1322906913754723003, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=13313213656@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906913846997693, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913754723003, language=EN, stringName=Zhan-jun DONG, firstName=Zhan-jun, middleName=null, lastName=DONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906913922495166, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, authorId=1322906913754723003, language=CN, stringName=董占军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河北省人民医院药学部，石家庄　050051, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906911632405160, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, xref=null, ext=[AuthorCompanyExt(id=1322906911670153897, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China), AuthorCompanyExt(id=1322906911691125418, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906909631722149, companyId=1322906911632405160, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河北省人民医院药学部，石家庄　050051)])])]

孙雪, 郭彩会, 宋浩静, 董占军

作者信息

河北省人民医院药学部，石家庄　050051

通讯作者:

董占军，男，主任药师，硕士生导师，主要从事药事管理及临床药学工作。E-mail：13313213656@126.com。

作者简介:

孙雪，女，主管药师，硕士，主要从事临床药理学工作。E-mail：804048521@qq.com。

Rivaroxaban-induced bleeding: analysis of literature in China and abroad

Xue SUN, Cai-hui GUO, Hao-jing SONG, Zhan-jun DONG

Affiliations

The Pharmaceutical Department of Hebei General Hospital, Shijiazhuang 050051, China

出版时间: 2021-11-15

文章导航

摘要

收起

目的：

分析利伐沙班致出血不良反应的发生情况及临床特点，为临床合理用药提供参考。

方法：

检索利伐沙班上市以来中国知网、维普、万方数据库、中国医院数据图书馆、PubMed和EMBase数据库收载的出血不良反应文献，进行统计分析。

结果：

利伐沙班致出血不良反应的有效文献报道共51篇，涉及59例患者；患者年龄分布以60岁以上居多（51例，86.44%）；出血多发生在用药后30 d内（27例，45.76%）；以脑出血多见（15例，25.42%）；目前以常规治疗最为普遍（26例，44.07%）；从治疗转归情况来看，1~7 d停止出血病例最多（29例，49.15%）；死亡病例共6例，以入院14 d内死亡居多（5例，83.33%）。

结论：

利伐沙班引起的出血不良反应需引起临床高度重视，需加强用药监测，以减少致命性出血不良反应的发生。

关键词

利伐沙班 / 出血 / 药物不良反应 / 文献分析

Abstract

收起

Objective:

To analyze the occurrence and clinical characteristics of bleeding induced by rivaroxaban in order to provide reference for clinical medication.

Methods:

Bleeding adverse reaction literature from CNKI, VIP, Chinese Hospital Data Library, Wanfang, PubMed and EMBase since the listing of rivaroxaban were collected and analyzed.

Results:

A total of 51 effective literature of report cases regarding bleeding ADR induced by rivaroxaban, involving 59 patients, were identified and included in the analysis. The majority of patients were over 60 years old (51 cases, 86.44%). Most of bleeding occurred within 30 days after medication (27 cases, 45.76%). Cerebral hemorrhage was commonly seen (15 cases, 25.42%). Conventional treatment is mostly applied (26 cases, 44.07%). In terms of treatment outcome, most bleeding stopped within 1 to 7 days (29 cases, 49.15%). There were 6 deaths, the majority of which occurred within 14 days of admission (5 cases, 83.33%).

Conclusion:

The bleeding ADR induced by rivaroxaban need to be highly valued in clinical, and drug monitoring need to be strengthened to reduce the occurrence of fatal bleeding ADR.

Key words

rivaroxaban / bleeding / adverse drug reactions / literature analysis

引用本文

孙雪, 郭彩会, 宋浩静, 董占军. 利伐沙班致出血不良反应的国内外文献分析. 中国新药杂志, 2021 , 30 (21) : 2003 -2008 .

Xue SUN, Cai-hui GUO, Hao-jing SONG, Zhan-jun DONG. Rivaroxaban-induced bleeding: analysis of literature in China and abroad[J]. Chinese Journal of New Drugs, 2021 , 30 (21) : 2003 -2008 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

MEMBERS AF, CAMM AJ, LIP GYH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33(21): 2719-2747.

[2]

黄卫娟, 何秀云, 陈海燕. 既往植入冠脉支架的非瓣膜病心房颤动患者抗栓策略现状调查[J]. 今日药学, 2015, 25(2): 134-136.

[3]

胡竹君, 胡晓晟. 参松养心胶囊联合美托洛尔及中度有氧运动对肥胖伴心房颤动患者炎症和氧化应激指标的影响[J]. 中国现代应用药学, 2019, 36(12): 1541-1545.

[4]

PATEL MR, MAHAFFEY KW, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10): 883-891.

[5]

FAUST AC, WOODARD S, KOEHL JL, et al. Managing subdural bleeding associated with rivaroxaban: a series of 3 cases[J]. J Pharm Pract, 2016, 29(3): 257-262.

[6]

STÖLLBERGER C, BASTOVANSKY A, FINSTERER J. Fatal intracerebral bleeding under rivaroxaban[J]. Int J Cardiol, 2015, 201: 110-112.

[7]

COHEN M, NEVO H, HERSHKO D, et al. Rivaroxaban-Induced Gastrointestinal Bleeding Presenting as Acute Colon Obstruction[J]. Pharmacology, 2017, 99(3-4): 124-127.

[8]

FRALICK M, JUURLINK DN, MARRAS T. Bleeding associated with coadministration of rivaroxaban and clarithromycin[J]. CMAJ, 2016, 188(9): 669-672.

[9]

SALEMIS NS. Rivaroxaban-induced chest wall spontaneous expanding hematoma[J]. Drug Discov Ther, 2017, 11(1): 47-50.

[10]

MCCARTER JA, BELL PR, MCCADDEN L, et al. Rivaroxaban and retropharyngeal haemorrhage[J]. BMJ Case Rep, 2016, 2016: bcr2015212446.

[11]

BÖREKCI E. Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report[J]. Afr Heal Sci, 2019, 19(2): 2290-2293.

[12]

LIU CY, SAMIMI DB, TAO JP. Hemorrhagic complications of rivaroxaban after eyelid surgery[J]. Ophthal Plast Reconstr Surg, 2016, 32(1): 74.

[13]

NAGARAJA V, CRANNEY G, KUSHWAHA V. Spontaneous splenic rupture due to rivaroxaban[J]. Drug Ther Bull, 2018, 56(11): 136-139.

[14]

DEEKONDA P, STOKES OM, CHAN D. Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation[J]. Eur Spine J, 2019, 28(4): 688-692.

[15]

KILIÇ S, SARAÇOČLU E, ALKAN G. A rare complication in a patient taking rivaroxaban: alveolar hemorrhage[J]. Turk Kardiyol Dern Ars, 2018, 46(1): 73-75.

[16]

JUN JH, HWANG JC. Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage[J]. JAMA Ophthal, 2015, 133(10): 1184-1186.

[17]

RUSCHEL LG, REGO FMMD, MILANO JB, et al. Spontaneous intracranial epidural hematoma during rivaroxaban treatment[J]. Rev Assoc Med Bras, 2016, 62(8): 721-724.

[18]

UTKEWICZ MD, BRUNETTI L, AWAD NI. Epistaxis complicated by rivaroxaban managed with topical tranexamic acid[J]. Am J Emerg Med, 2015, 33(9): 1329.e5-e7.

[19]

YAMAGUCHI Y, KOGA M, MATSUKI T, et al. Intracranial subdural hematomas with elevated rivaroxaban concentration and subsequently detected spinal subdural hematoma: a case report[J]. Thromb Res, 2016, 143: 127-129.

[20]

BANG WS, KIM KT, PARK MK, et al. Acute spinal subdural hematoma in a patient taking rivaroxaban[J]. J Korean Med Sci, 2018, 33(5): e40.

[21]

SHIVAMURTHY P, BRAR N, THERRIEN ML. Isolated hemopericardium associated with rivaroxaban: first case report[J]. Pharmacotherapy, 2014, 34(9): e169-e172.

[22]

KHAM NM, SONG M. SPONTANEOUS. Life-threatening hemorrhagic cardiac tamponade secondary to rivaroxaban[J]. Am J Ther, 2016, 23(4): e1128-e1131.

[23]

KAUFFMANN S, CHABANNE R, COSTE A, et al. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation[J]. A A Case Rep, 2015, 4(11): 151-154.

[24]

ATIA R, BONNEL S, VALLOS M, et al. Spontaneous choroidal hemorrhage associated with novel oral anticoagulants: a report of two cases and literature review[J]. J Fr Ophtalmol, 2018, 41(8): 767-772.

[25]

DARGAZANLI C, LONJON N, GRAS-COMBE G. Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management[J]. Eur Spine J, 2016, 25(Suppl 1): S100-S103.

[26]

CASTILLO JM, AFANADOR HF, MANJARREZ E, et al. Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban[J]. Am J Case Rep, 2015, 16: 377-381.

[27]

ISLAM M, BANGAR M, SHILOH AL. A woman in her 70s on anticoagulation with sudden shock[J]. Chest, 2019, 155(5): e123-e126.

[28]

SHIEH WS, SRIDHAR J, HONG BK, et al. Ophthalmic complications associated with direct oral anticoagulant medications[J]. Semin Ophthalmol, 2017, 32(5): 614-619.

[29]

ISMAIL R, ZAGHRINI E, HITTI E. Spontaneous spinal epidural hematoma in a patient on rivaroxaban: case report and literature review[J]. J Emerg Med, 2017, 53(4): 536-539.

[30]

LAKATOS B, STOECKLE M, ELZI L, et al. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus[J]. Swiss Med Wkly, 2014, 144: w13906.

[31]

STÖLLBERGER C, ZUNTNER G, BASTOVANSKY A, et al. Cerebral hemorrhage under rivaroxaban[J]. Int J Cardiol, 2013, 167(6): e179-e181.

[32]

ALIDOOST M, SOOMRO R, GUBELADZE A, et al. Rivaroxaban related bilateral adrenal hemorrhage: a rare complications of direct oral anticoagulants——a case reports[J]. Am J Case Rep, 2019, 20: 1607-1611.

[33]

XU B, MACISAAC A. Life-threatening haemorrhagic pericarditis associated with rivaroxaban[J]. Int J Cardiol, 2014, 174(2): e75-e76.

[34]

ÇALIŞKAN F, AKDEMIR HU, NURATA H, et al. Rivaroxaban-induced severe diffuse intracerebral hemorrhage[J]. Am J Emerg Med, 2015, 33(3): 475.e1-e5.

[35]

SALDANHA I, MATOS R, ÓRFÃO T, et al. Tympanic membrane haematoma in a RivaroxabanTreated patient: a case report[J]. Acta Med Port, 2019, 32(6): 469-470.

[36]

KOCAYIGIT I, CAN Y, SAHINKUS S, et al. Spontaneous rectus sheath hematoma during rivaroxaban therapy[J]. Indian J Pharmacol, 2014, 46(3): 339-340.

[37]

WONG A, KOUTSOGIANNIS Z, GREENE SL. Pulmonary haemorrhage from therapeutic rivaroxaban use: chest radiograph consolidation is not always infection![J]. Emerg Med Australas, 2014, 26(3): 318-319.

[38]

PURRUCKER JC, CAPPER D, BEHRENS L, et al. Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy[J]. Am J Emerg Med, 2014, 32(8): 947.e3-947.e5.

[39]

GONZVA J, PATRICELLI R, LIGNAC D. Spontaneus splenic rupture in a patient treated with rivaroxaban[J]. Am J Emerg Med, 2014, 32(8): 950.e3.

[40]

OLIVIER J, YAKOUBI R, GRAS S, et al. Critical haematuria after prostate biopsies with RIVAROXABAN. Case report[J]. Progres En Urol, 2013, 23(12): 1012-1014.

[41]

LO JC, GERONA RR. A case of rivaroxaban associated intracranial hemorrhage[J]. West J Emerg Med, 2014, 15(4): 375-377.

[42]

JAEGER M, JEANNERET B, SCHAEREN S. Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban)[J]. Eur Spine J, 2012, 21(Suppl 4): S433-S435.

[43]

YILDIZ İ, AKSU E, ÖZMEN YILDIZ PÖ, et al. A case of rivaroxaban associated spontaneous hemothorax[J]. Turk Gogus Kalp Damar Cerrahisi Derg, 2019, 27(1): 118-120.

[44]

BOLAND M, MURPHY M, MURPHY M, et al. Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report[J]. J Med Case Rep, 2012, 6(1): 129.

[45]

LY BA, QUINTERO L. Adrenal insufficiency from unilateral adrenal hemorrhage in a patient on rivaroxaban thromboprophylaxis[J]. AACE Clin Case Rep, 2019, 5(1): e70-e72.

[46]

COMUTH W, CHRISTIANSEN JJ, BLOCH-MÜNSTER AM, et al. Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban[J]. Blood Coagul Fibrinolysis, 2017, 28(1): 102-104.

[47]

RADCLIFF KE, ONG A, PARVIZI J, et al. Rivaroxaban-induced epidural hematoma and cauda equina syndrome after total knee arthroplasty: a case report[J]. Orthop Surg, 2014, 6(1): 69-71.

[48]

ZAAROUR M, HASSAN S, THUMALLAPALLY N, et al. Rivaroxaban-induced nontraumatic spinal subdural hematoma: an uncommon yet life-threatening complication[J]. Case Rep Hematol, 2015, 2015: 275380.

[49]

KODAIRA M, YAMAZAKI H, TABEI R, et al. Pathological Findings of Rivaroxaban-Associated Hemorrhagic Pericarditis[J]. Circ J, 2018, 82(11): 2917-2918.

[50]

GIUSTOZZI M, VEDOVATI MC, AGNELLI G. Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report[J]. Blood Coagul Fibrinolysis, 2018, 29(4): 391-394.

[51]

AMIN A, SAFAYA A, RONNY F, et al. Hemorrhagic shock from spontaneous splenic rupture requiring open splenectomy in a patient taking rivaroxaban[J]. Am Surg, 2016, 82(2): E54-E55.

[52]

HANA A, BERTHOLD C, GUNNESS VR, et al. NOAC and intracerebral bleeding: presentation of four cases and review of the literature[J]. Bull Soc Sci Med Grand Duche Luxemb, 2014, 2014(1): 57-66.

[53]

ELIKOWSKI W, MAŁEK M, SKOWROŃSKI M, et al. Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease[J]. Pol Merkur Lekarski, 2015, 39(232): 227-230.

[54]

杜青青, 王娜, 钱妍. 利伐沙班致尿路出血1例[J]. 中国医院药学杂志, 2019, 39(16): 1709-1711.

[55]

左丽, 邢惟青, 王茜, 等. 利伐沙班致严重胃肠道出血死亡病例分析[J]. 中国临床药理学杂志, 2019, 35(6): 571-572.

[56]

KUBITZA D, BECKA M, ROTH A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban: an oral, direct factor Xa inhibitor[J]. J Clin Pharmacol, 2013, 53(3): 249-255.

[57]

HALPERIN JL, HANKEY GJ, WOJDYLA DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (rocket af)[J]. Circulation, 2014, 130(2): 138-146.

[58]

KVASNICKA T, MALIKOVA I, ZENAHLIKOVA Z, et al. Rivaroxaban-metabolism, pharmacologic properties and drug interactions[J]. Curr Drug Metab, 2017, 18(7): 636-642.

[59]

MAJEED A, ÅGREN A, HOLMSTRÖM M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study[J]. Blood, 2017, 130(15): 1706-1712.

[60]

SHEIKH-TAHA M. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate[J]. Intern Emerg Med, 2019, 14(2): 265-269.

[61]

HEO YA. Andexanet Alfa: first global approval[J]. Drugs, 2018, 78(10): 1049-1055.

2021年第30卷第21期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-11-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-03-19

基金

作者信息

河北省人民医院药学部，石家庄　050051

通讯作者:

董占军，男，主任药师，硕士生导师，主要从事药事管理及临床药学工作。E-mail：13313213656@126.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906909631722149

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT